自身免疫性血小板减少症患者的克隆性造血:一项国际多中心研究
该国际多中心回顾性观察研究纳入167例意大利、英国和美国的成人免疫性血小板减少症(ITP)患者,中位病程3.6年后行二代测序,18.5%检出克隆性造血,与高龄男性、更早启用二线治疗(尤其TPO-RA)及血栓风险升高相关。
要点
- 167例ITP患者中18.5%存在克隆性造血,常见突变基因为TET2、DNMT3A、SRSF2和ASXL1。
- 克隆性造血患者更常见于高龄男性,且从一线到二线治疗时间更短,尤其使用TPO-RA者。
- 克隆性造血与血栓风险升高相关(26% vs 8%,P=0.01),独立于TPO-RA暴露,但存在年龄效应。
核心结论
- 成人ITP患者中克隆性造血患病率为18%,与高龄、复发/难治性疾病及高血栓并发症风险相关。
研究设计与样本
- 多中心回顾性观察研究,纳入167例在意大利、英国和美国13个中心随访的成人ITP患者。
- 患者在中位病程3.6年后接受二代测序评估,83%曾接受至少1线治疗,中位治疗线数2线(范围0-9)。
主要发现
- 167例中51例(30%)检出至少1个突变,排除胚系变异和多态性后,31例(18.5%)定义为克隆性造血。
- 最常见突变基因为TET2、DNMT3A、SRSF2和ASXL1(中位变异等位基因频率29%);31例中19例(68%)为高风险变异,8例有多个突变。
- 突变患者更常见于高龄男性,从一线到二线治疗时间更短,尤其使用TPO-RA者。
- 克隆性造血与血栓风险升高相关(26% vs 8%,P=0.01),独立于TPO-RA暴露,但存在年龄效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnostic boundaries between immune thrombocytopenia (ITP) and other thrombocytopenic states, such as thrombocytopenic myelodysplastic syndromes, may be difficult to establish, and the detection of somatic mutations by next-generation sequencing (NGS) may be of aid. Here, we aimed at characterizing the prevalence and clinical significance of clonal hematopoiesis in ITP. In this multicentric retrospective observational study, we enrolled 167 adult patients with ITP, followed at 13 centers in Italy, United Kingdom, and the United States. Patients underwent NGS evaluation after a median of 3.6 years from ITP onset, and 83% had received at least 1 therapy line, for a median of 2 lines (range, 0-9); 51 of 167 patients (30%) had at least 1 mutation. After exclusion of germ line variants and polymorphisms, 31 of 167 (18.5%) were defined as having clonal hemopoiesis. Most commonly mutated genes were TET2, DNMT3A, SRSF2, and ASXL1 (median variant allele frequency, 29%); 19 of 31 patients (68%) had high-risk variants, and 8 had multiple mutations. Mutated patients were more frequently older males and showed a shorter time from first to second-line therapy, particularly with thrombopoietin receptor agonist (TPO-RA). Additionally, clonal hematopoiesis was associated with increased thrombotic risk (26% vs 8% in NGS-negative cases; P = .01), independently from TPO-RA exposure, though with an age effect. These data demonstrated the prevalence of clonal hematopoiesis in 18% of adult patients with ITP, which is associated with older age, relapsed/refractory disease, and high risk of thrombotic complications.
引用
- Fattizzo B, Marchetti A, Bosi A, et al. Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study. Blood Adv. 2025. PMID: 39536292. doi:10.1182/bloodadvances.2024014984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。